RACGP
Aleisha Orr

Aleisha Orr

TGA approves second oral GLP-1

Another GLP-1 pill option will soon be available in Australia, this time for both weight loss and type 2 diabetes.

GLP-1 pill and injectable

The approval of Foundayo, a daily medication used in weight management, comes within two weeks of the approval of a Wegovy pill for the first time in Australia.

The Elli Lily produced medication was approved by the TGA on November 16. Foundayo's active ingredient is orforglipron and has been approved for both weight loss and type 2 diabetes at a 9mg dose.

The pill can be taken daily, rather than the injectable GLP-1s that are currently available for weekly administration.

Wegovy pills, which are semaglutide, have been approved in doses of 1.5mg, 4mg, 9mg and 25mg for weight management and cardiovascular risk reduction.

Associate Professor Samantha Hocking, President of the National Association of Clinical Obesity Services, welcomed the availability of the new medicine, noting that overweight and obesity had overtaken smoking as the leading risk factor for disease burden in Australia.

“Australia is grappling with rising rates of overweight and obesity, which now affect around 13 million adults,” she said.

AD

“Obesity is a complex chronic disease that increases the risk of at least 30 other serious medical conditions, ranging from cancer and cardiovascular disease to type 2 diabetes.

“The impact of obesity and type 2 diabetes on individuals, families and our health system highlights the urgent need for stronger prevention efforts and improved access to clinically proven treatment options.”

Upon the TGA's approval of Wegovy endocrinologist Dr Michael Hancock had told Medical Forum he was expecting other oral incretin therapies to also be approved.

He said the availability of oral medications would provide "benefit to those who found it difficult to use injections". 

Originally used for management of diabetes, the use of GLP-1s in Australia for the management of weight has taken off since the first product was approved for use in 2018. 

A study from UNSW Sydney published earlier this year found almost half a million Australians prescribed a GLP-1 were using the medications for weight management.

AD